Viking Therapeutics To Highlight Data From Phase 1 Clinical Trial Of Dual GLP-1/GIP Receptor Agonist VK2735 In Oral Presentation At ObesityWeek 2023
Portfolio Pulse from Benzinga Newsdesk
Viking Therapeutics, Inc. (NASDAQ:VKTX) announced that data from the Phase 1 clinical trial of VK2735, a dual GLP-1/GIP receptor agonist, will be presented at ObesityWeek 2023. The presentation will highlight VK2735's safety, tolerability, and pharmacodynamic effects in healthy volunteers. New findings related to the impact of VK2735 on liver fat content and plasma lipid levels will also be reported.
October 10, 2023 | 8:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viking Therapeutics' announcement of the presentation of Phase 1 trial data of VK2735 at ObesityWeek 2023 could potentially boost investor confidence in the company's research and development capabilities.
The announcement of the presentation of Phase 1 trial data of VK2735 at a major conference like ObesityWeek 2023 indicates that Viking Therapeutics is making progress in its research and development efforts. This could potentially boost investor confidence in the company's capabilities and future prospects, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100